Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Preveceutical Medical Inc PRVCF


Primary Symbol: C.PREV

PreveCeutical Medical Inc. is a Canada-based health sciences company. The Company’s principal business activity is the development of options for preventive and curative therapies utilizing organic and nature identical products. The Company’s pipeline includes Cannabinoid Sol-Gel, Non-Addictive Analgesic, BSV Peptide Program and Dual Gene Therapy. Its Cannabinoid Sol-Gel is a cannabinoid-based... see more

Recent & Breaking News (CSE:PREV)

IIROC Trading Halt - PREV

Canada NewsWire May 4, 2020

PreveCeutical Confirms its First Peptide with Promising Pre-Clinical Efficacy as a Non-Addictive Painkiller

Newsfile April 29, 2020

PreveCeutical Announces Patent Cooperation Treaty ("PCT") Application

Newsfile February 24, 2020

PreveCeutical Retains Patent Legal Team

Newsfile January 23, 2020

PreveCeutical Announces Further Updates to the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program

Newsfile January 14, 2020

PreveCeutical Announces Positive Results Following a Preliminary Safety Evaluation of Sol-Gel Formulations When Applied to Human Nasal Tissue

Newsfile January 8, 2020

IIROC Trade Resumption - PREV

Canada NewsWire October 29, 2019

PreveCeutical Announces Successful Completion from its Design, Synthesis and Preliminary Evaluation of Novel Designed Peptides Derived from Caribbean Blue Scorpion Venom in a Cell-Based Brain Cancer Model

Newsfile October 29, 2019

IIROC Trading Halt - PREV

Canada NewsWire October 29, 2019

PreveCeutical Receives $616,802 AUD Research and Development Tax Incentive Cash Refund

Newsfile October 7, 2019

PreveCeutical Announces the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program

Newsfile September 23, 2019

PreveCeutical Reaches Milestone in Research Program for Development of Non-Addictive Analgesics

Newsfile September 3, 2019

IIROC Trade Resumption - PREV

Canada NewsWire August 6, 2019

PreveCeutical Grants Asterion Option to Purchase up to a 51% Interest in Sol-Gel Intellectual Property

Newsfile August 6, 2019

IIROC Trading Halt - PREV

Canada NewsWire August 6, 2019

PreveCeutical Named in Lawsuit

Newsfile July 19, 2019

PreveCeutical Successfully Incorporates Medicinal Cannabis Extracts into the Sol-Gel Drug Delivery System

Newsfile July 9, 2019

PreveCeutical Announces Appointment of New Directors

Newsfile June 21, 2019

PreveCeutical Announces Further Positive Results from its Dual Gene Therapy Research Program

Newsfile June 17, 2019

PreveCeutical Secures $300,000 Loan and Resignation of a Director

Newsfile June 3, 2019